S&P 500 Healthcare Sector SEC Filings — February 12, 2026

13-02-2026

Moderna, Inc. filed an 8-K on February 13, 2026 (AccNo: 0001682852-26-000015), reporting results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. No specific revenue, earnings, balance sheet details, guidance, period-over-period comparisons, or other quantitative financial metrics are disclosed in the provided filing information. No positive, negative, or flat performance indicators were mentioned.

• ·AccNo: 0001682852-26-000015
• ·Sector: not specified

13-02-2026

Sound Financial Bancorp, Inc. filed a Form 8-K on February 13, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other events, transaction values, financial metrics, or exhibits are disclosed in the provided filing information. This is a multi-item filing with limited transparency on content.

13-02-2026

SunHydrogen, Inc. filed an 8-K on February 13, 2026 (AccNo: 0001213900-26-015747, Size: 380 KB), reporting under Item 1.01 entry into a material definitive agreement and under Item 9.01 financial statements and exhibits. No specific details on the agreement, transaction value, parties, financial impacts, or other metrics are disclosed. This is a multi-item mandatory filing with no period-over-period comparisons or quantitative data provided.

13-02-2026

News Corp filed an 8-K on February 13, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other events or the contents of the exhibits are disclosed. No financial metrics, transactions, or performance data are provided.

13-02-2026

LCI Industries filed an 8-K on February 13, 2026 (AccNo: 0000763744-26-000004, size 705 KB), disclosing an officer change under Item 5.02 covering departure of directors or certain officers, election or appointment of directors/officers, and compensatory arrangements of certain officers. The filing also includes Regulation FD disclosure under Item 7.01 and financial statements and exhibits under Item 9.01. No specific details on affected positions, individuals, reasons for change, or financial metrics are disclosed.

• ·Event date: February 13, 2026
• ·Source: us_sec
• ·Sector: not specified

13-02-2026

Citius Oncology, Inc. filed an 8-K on February 13, 2026 (AccNo: 0001213900-26-015894), reporting results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. No specific revenue, earnings, balance sheet details, guidance, period-over-period comparisons, or other quantitative financial metrics are disclosed in the provided filing information. This represents a standard voluntary disclosure of financial results.

13-02-2026

Citius Pharmaceuticals, Inc. filed a Form 8-K on February 13, 2026 (AccNo: 0001213900-26-015895), disclosing under Item 3.01 a notice of delisting or failure to satisfy a continued listing rule or standard, and under Item 2.02 results of operations and financial condition. Item 9.01 references financial statements and exhibits. This multi-item filing highlights a material compliance failure with exchange listing requirements, with no specific financial metrics or performance details provided.

• ·Multi-item 8-K filing (Items 2.02, 3.01, 9.01)
• ·Event date aligns with filing date: 2026-02-13

13-02-2026

Bogota Financial Corp. filed a Form 8-K on 2026-02-13 under Item 2.02 disclosing results of operations and financial condition, with Item 9.01 providing financial statements and exhibits. This is a standard voluntary disclosure for financial results. No specific quantitative metrics, period-over-period changes, or other details are provided in the filing summary.

13-02-2026

CBL & Associates Properties Inc filed an 8-K on February 13, 2026, disclosing Results of Operations and Financial Condition under Item 2.02, with Financial Statements and Exhibits attached under Item 9.01. No specific revenue, earnings, balance sheet details, period-over-period comparisons, or guidance were mentioned in the filing description. This is a standard earnings-related disclosure without quantified metrics provided.

13-02-2026

Louisiana-Pacific Corp filed an 8-K on February 13, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other events or the content of the exhibits are disclosed in the provided filing summary. This is a multi-item filing with no quantitative metrics, transaction details, or performance comparisons mentioned.

13-02-2026

Columbus Circle Capital Corp II filed a Form 8-K on February 13, 2026, disclosing multiple material events under Items 1.01 (Entry into a Material Definitive Agreement), 3.02 (Unregistered Sales of Equity Securities), 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), 5.03 (Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). No specific details, transaction values, personnel names, financial metrics, or quantitative impacts are disclosed in the provided filing summary. This multi-item filing signals several corporate developments but lacks data for directional assessment.

13-02-2026

Exact Sciences Corp filed a Form 8-K on February 13, 2026, under Item 2.02 disclosing results of operations and financial condition, and Item 9.01 for financial statements and exhibits. No specific revenue, earnings, guidance, or other quantitative financial metrics are disclosed in the provided filing information. This appears to be a standard earnings-related disclosure with no detailed operational or balance sheet impacts provided.

13-02-2026

Bayview Acquisition Corp filed an 8-K on February 13, 2026, disclosing under Item 2.03 the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement. No specific details such as amounts, terms, parties involved, or connection to any merger/acquisition are provided in the filing summary. Sector is not specified.

13-02-2026

Newell Brands Inc. filed a Form 8-K on 2026-02-13 disclosing matters under Item 5.02 related to departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. Item 9.01 indicates financial statements and exhibits were included. No specific details on affected positions, individuals involved, reasons for changes, or any quantitative metrics are disclosed.

13-02-2026

Society Pass Incorporated filed an 8-K on February 13, 2026, disclosing under Item 1.01 entry into a material definitive agreement, under Item 8.01 other events, and under Item 9.01 financial statements and exhibits. No specific details on the agreement, events, transaction value, financial impacts, or quantitative metrics are disclosed in the provided filing summary. This multi-item filing signals potentially significant developments, but lacks context for directional assessment.

13-02-2026

Disc Medicine, Inc. filed a Form 8-K on February 13, 2026 (AccNo: 0001193125-26-051504, Size: 307 KB), reporting under Items 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific details on events, transactions, financial metrics, or impacts disclosed in the provided information. No quantitative data, comparisons, or scheduled events are mentioned.

13-02-2026

Werewolf Therapeutics, Inc. filed an 8-K on February 13, 2026, disclosing costs associated with exit or disposal activities under Item 2.05, officer or director changes including departures, elections, appointments, or compensatory arrangements under Item 5.02, and Regulation FD disclosure under Item 7.01. No specific details on personnel changes, reasons, costs, or financial impacts are disclosed. This combination signals potential restructuring but lacks quantification for assessment.

13-02-2026

MVB Financial Corp filed an 8-K on February 13, 2026 (AccNo: 0001277902-26-000013, Size: 3 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing involving voluntary disclosure of material non-public information with attached exhibits. No specific transaction details, financial metrics, or quantitative data are disclosed in the filing summary.

13-02-2026

GCI Liberty, Inc. filed an 8-K on February 13, 2026, under Item 5.04 disclosing a temporary suspension of trading under the registrant's employee benefit plans. Item 9.01 reports financial statements and exhibits, but no specific details, financial metrics, or quantitative impacts are provided. This is an informational filing with no disclosed positive or negative performance metrics.

13-02-2026

IDEXX Laboratories Inc./DE filed an 8-K on February 13, 2026 (AccNo: 0000874716-26-000007, Size: 276 KB) under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on positions affected, individuals involved, reasons for change, timing, or quantitative impacts are disclosed. This is a routine governance disclosure with no financial metrics or performance data provided.

13-02-2026

BayFirst Financial Corp. filed an 8-K on 2026-02-13 disclosing under Item 5.02 a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. Item 9.01 references financial statements and exhibits. No specific details on the individuals involved, reasons for change, timing, or impacts are disclosed.